Overview / Abstract: |
New developments in the role of mutations in the epidermal growth factor receptor (EGFR) gene are transforming the understanding of how NSCLC progresses as a disease. This insight has enabled NSCLC to evolve from an untreatable disease to one where a number of novel therapeutic options are available, and individualized treatment regimens are now offered to optimize care. This digital flipbook includes pertinent data and video insights into new and practice-changing therapy in the setting of epidermal EGFR mutation-positive NSCLC. Discussion topics include first-line therapy selection, mechanisms of resistance to EGFR TKIs, EGFR TKI therapy beyond progression, and third-generation EGFR TKIs under investigation. Upon completion of this activity, participants will be able to: This is a targeted activity for physicians to learn about and be updated on new and emerging TKI agents for treatment of NSCLC in the first-, second- and third-line based on the most recent data. |
Expiration |
Sep 25, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Radiology / RAD Tech CE, Respiratory Therapy CE |
Format |
Book, Journal, Monograph, New Procedures, Online, Podcast, Webinar / Webcast / Video, Workbook |
Credits / Hours |
1.0 |
Accreditation |
AMA PRA Category 1 Credit |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
George R. Simon, MD, FACP, FCCP H. Jack West, MD |
Activity Specialities / Related Topics |
Acute Care, Asthma, Education / Teaching, Hematology, Immunology / Immunosuppression, Oncology / Cancer / Radiation Therapy, Pulmonary Medicine / COPD, Radiology / Imagery / Nuclear Medicine, Surgery |
Sponsors / Supporters / Grant Providers |
Sponsored by the University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Pfizer, Inc. |
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, NSCLC, lung cancer, tyrosine kinase inhibitors, epidermal growth factor receptor, EGFR, erlotinib, gefitinib, afatinib, osimertinib, dacomitinib, EGF816, nazartinib, olmutinib, ASP8273, lorlatinib, brigatinib, PF-06747775, avitinib, EGFR T790M, EGFR C797S, ACHL, Pfizer, West, Simon, Jack West, George Simon, MD Anderson, UTMDA, MDA Free CE CME Live CE CME |